The present study further demonstrates that the combination treatment modulates the expression of the tumor receptor signaling molecules, including TGF-β/TβR-2, AXL/Gas6, and Wnt/FZD/β-catenin/GSK-3β, in LLC1 tumor tissues. This evidence concerns the gene GSK3B and neoplasm.